We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced preliminary financial results for fourth-quarter 2021 on Jan 11. Following this release, shares of the company are down 15.4% till the last trading.
The company is expected to release the Q4 and 2021 results in mid-February.
Prelim Q4 in Detail
As per the preliminary report, fourth-quarter revenues are likely to be about $36 million, reflecting a year-over-year improvement of 33%. The Zacks Consensus Estimate of $35.9 million remains below the preliminary figure.
During the fourth quarter, PacBio confirmed placing a record 48 Sequel II/IIe systems, up 37.1% from the year-ago period.
Preliminary instrument revenues for the fourth quarter of 2021 are expected to be around $16.2 million, up 19.1% year over year, while consumables revenues are likely to be nearly $15 million, up 50% year over year.
Preliminary service and other revenues for the fourth quarter of 2021 are expected to be approximately $4.8 million, up 37.1% from the prior-year period.
Per management, the fourth quarter reflected the company’s sustained execution of its goals. The company launched the COVID-19 surveillance solution, HiFi Viral, which is PacBio’s first kitted sequencing solution. The company also made noteworthy progress in developing its short-read sequencing platform by applying a new clustering method to facilitate a more robust workflow. Based on this early success, PacBio remains on track to launch its new short-read Sequencing by Binding (“SBB”) technology in 2023.
Full-Year Prelim Results
Per PacBio, its full-year total revenues are likely to be $130.5 million, up 65% from the comparable figure in 2020. The Zacks Consensus Estimate of $130.4 million remains below the preliminary figure.
Based on PacBio’s placement of the Sequel II/IIe systems in the fourth quarter, the company’s installed base was 374 units as of Dec 31, 2021, reflecting an improvement of 84.2% from the comparable figures in 2020.
Our Take
PacBio’s impressive preliminary fourth-quarter performance projections raise our optimism. The company’s plans to launch new library prep and sequencing kits for the Sequel II/IIe platform (which will reduce DNA input requirements as well as simplify workflow) in the first half of 2022 are encouraging. PacBio’s confirmation of developing important improvements to the Sequel II/IIe platform that will be released in the first half of 2022 is also promising.
PacBio finalizing the expansion of its collaboration with Invitae Corporation to include the former’s proprietary short-read sequencing platform, Sequencing by Binding, along with its collaboration with Twist Bioscience to deliver optimized HiFi-enabled target capture workflows, are impressive. These activities further raise our optimism on the stock.
The company’s success regarding the SBB technology, along with its plans of leveraging the foundation that it built in 2021 and entering the late stages of development for multiple new sequencing platforms buoys our optimism.
Price Performance
Shares of the company have lost 20.8% between October and December 2021 against the industry’s 5.4% growth and the S&P 500’s 8.9% rise.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, PacBio carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Cerner Corporation and Catalent, Inc. (CTLT - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.51%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 6.4% against the industry’s 15.8% fall between October and December 2021.
Cerner, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.3%. CERN’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 3.21%.
Cerner has gained 32% against the industry’s 3.7% fall between October and December 2021.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.88%. It currently carries a Zacks Rank #2.
Catalent has lost 2.9% compared with the industry’s 4.1% fall between October and December 2021.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
PacBio (PACB) Reports Impressive Preliminary Q4, FY21 Revenues
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced preliminary financial results for fourth-quarter 2021 on Jan 11. Following this release, shares of the company are down 15.4% till the last trading.
The company is expected to release the Q4 and 2021 results in mid-February.
Prelim Q4 in Detail
As per the preliminary report, fourth-quarter revenues are likely to be about $36 million, reflecting a year-over-year improvement of 33%. The Zacks Consensus Estimate of $35.9 million remains below the preliminary figure.
During the fourth quarter, PacBio confirmed placing a record 48 Sequel II/IIe systems, up 37.1% from the year-ago period.
Preliminary instrument revenues for the fourth quarter of 2021 are expected to be around $16.2 million, up 19.1% year over year, while consumables revenues are likely to be nearly $15 million, up 50% year over year.
Preliminary service and other revenues for the fourth quarter of 2021 are expected to be approximately $4.8 million, up 37.1% from the prior-year period.
Per management, the fourth quarter reflected the company’s sustained execution of its goals. The company launched the COVID-19 surveillance solution, HiFi Viral, which is PacBio’s first kitted sequencing solution. The company also made noteworthy progress in developing its short-read sequencing platform by applying a new clustering method to facilitate a more robust workflow. Based on this early success, PacBio remains on track to launch its new short-read Sequencing by Binding (“SBB”) technology in 2023.
Full-Year Prelim Results
Per PacBio, its full-year total revenues are likely to be $130.5 million, up 65% from the comparable figure in 2020. The Zacks Consensus Estimate of $130.4 million remains below the preliminary figure.
Based on PacBio’s placement of the Sequel II/IIe systems in the fourth quarter, the company’s installed base was 374 units as of Dec 31, 2021, reflecting an improvement of 84.2% from the comparable figures in 2020.
Our Take
PacBio’s impressive preliminary fourth-quarter performance projections raise our optimism. The company’s plans to launch new library prep and sequencing kits for the Sequel II/IIe platform (which will reduce DNA input requirements as well as simplify workflow) in the first half of 2022 are encouraging. PacBio’s confirmation of developing important improvements to the Sequel II/IIe platform that will be released in the first half of 2022 is also promising.
PacBio finalizing the expansion of its collaboration with Invitae Corporation to include the former’s proprietary short-read sequencing platform, Sequencing by Binding, along with its collaboration with Twist Bioscience to deliver optimized HiFi-enabled target capture workflows, are impressive. These activities further raise our optimism on the stock.
The company’s success regarding the SBB technology, along with its plans of leveraging the foundation that it built in 2021 and entering the late stages of development for multiple new sequencing platforms buoys our optimism.
Price Performance
Shares of the company have lost 20.8% between October and December 2021 against the industry’s 5.4% growth and the S&P 500’s 8.9% rise.
Zacks Rank & Key Picks
Currently, PacBio carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Cerner Corporation and Catalent, Inc. (CTLT - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.51%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 6.4% against the industry’s 15.8% fall between October and December 2021.
Cerner, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 13.3%. CERN’s earnings surpassed estimates in three of the trailing four quarters, the average surprise being 3.21%.
Cerner has gained 32% against the industry’s 3.7% fall between October and December 2021.
Catalent has an estimated long-term growth rate of 16.9%. CTLT’s earnings surpassed estimates in the trailing four quarters, the average surprise being 9.88%. It currently carries a Zacks Rank #2.
Catalent has lost 2.9% compared with the industry’s 4.1% fall between October and December 2021.